Biomerica (BMRA) EBIT (2010 - 2026)

Biomerica (BMRA) has 17 years of EBIT data on file, last reported at -$1.3 million in Q1 2026.

• For the quarter ending Q1 2026, EBIT fell 7.27% year-over-year to -$1.3 million; the trailing twelve-month figure through Feb 2026 stood at -$5.4 million (down 4.98% YoY), and the FY2025 full-year result was -$5.1 million, up 19.32% from the prior year.
• EBIT improved to -$1.3 million in Q1 2026, from -$1.4 million in the prior quarter.
• In the past five years, EBIT ranged from a high of -$107499.0 in Q1 2022 to a low of -$2.1 million in Q3 2022.
• A 5-year average of -$1.4 million and a median of -$1.5 million in 2024 frame the typical range for EBIT.
• Across the five-year window, EBIT surged 95.04% in 2022 and plunged 1435.83% in 2023, its largest moves.
• Tracing BMRA's EBIT over 5 years: stood at -$1.7 million in 2022, then increased by 3.48% to -$1.6 million in 2023, then surged by 38.25% to -$993000.0 in 2024, then plunged by 38.27% to -$1.4 million in 2025, then rose by 5.46% to -$1.3 million in 2026.
• Business Quant data shows BMRA's EBIT at -$1.3 million in Q1 2026, -$1.4 million in Q4 2025, and -$1.1 million in Q3 2025.